65/100 · Elevated
Manufactured by ANI Pharmaceuticals, Inc.
Glipill Safety Profile: Moderate Concern with Common Gastrointestinal and Hypoglycemia Reactions
96,589 FDA adverse event reports analyzed
Last updated: 2026-05-12
GLIPIZIDE TABLETS is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by ANI Pharmaceuticals, Inc.. Based on analysis of 96,589 FDA adverse event reports, GLIPIZIDE TABLETS has a safety score of 65 out of 100. This moderate score indicates a notable volume of adverse event reports that patients and providers should be aware of. The most commonly reported adverse reactions for GLIPIZIDE TABLETS include BLOOD GLUCOSE INCREASED, NAUSEA, DRUG INEFFECTIVE, DIARRHOEA, FATIGUE. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for GLIPIZIDE TABLETS.
Glipizide-Tablets has a safety concern score of 65 out of 100, placing it in the elevated concern category based on analysis of FDA adverse event data. The FDA has received approximately 96,589 adverse event reports for this medication, which is primarily manufactured by Ani Pharmaceuticals, Inc..
The most commonly reported adverse events include Blood Glucose Increased, Nausea, Drug Ineffective. Of classified reports, 54.7% were designated as serious by the FDA, meaning they involved hospitalization, disability, or other significant medical outcomes. Glipill tablets are associated with a high incidence of gastrointestinal side effects such as nausea, diarrhea, and vomiting.
Hypoglycemia is a significant concern, with 1,145 reports of this adverse event. The drug is also linked to serious conditions like chronic kidney disease and acute kidney injury, though less frequently reported.
Patients taking Glipizide-Tablets should monitor for the commonly reported side effects and contact their healthcare provider if they experience any unusual symptoms. Glipill may interact with other drugs, such as beta-blockers, ACE inhibitors, and diuretics, potentially leading to hypoglycemia or other adverse effects. Patients should inform their healthcare provider of all medications they are taking. This analysis is based on voluntary FDA adverse event reports and should not replace professional medical advice.
Glipizide-Tablets received a safety concern score of 65/100 (elevated concern). This is based on a 54.7% serious event ratio across 50,703 classified reports. The score accounts for 96,589 total adverse event reports and 100 distinct reaction types. This elevated score indicates a notable proportion of serious adverse events and warrants careful monitoring.
Adverse event reports by sex: Female: 24,254, Male: 24,032, Unknown: 127. The most frequently reported age groups are age 70 (1,120 reports), age 67 (1,093 reports), age 72 (1,066 reports). These demographics reflect reporting patterns and may not represent the full patient population.
Out of 50,703 classified reports for GLIPIZIDE TABLETS:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
Glipill may interact with other drugs, such as beta-blockers, ACE inhibitors, and diuretics, potentially leading to hypoglycemia or other adverse effects. Patients should inform their healthcare provider of all medications they are taking.
If you are taking Glipizide-Tablets, here are important things to know. The most commonly reported side effects include blood glucose increased, nausea, drug ineffective, diarrhoea, fatigue. While many of these may be mild and temporary, you should contact your healthcare provider if any symptoms are severe or persistent. Monitor blood glucose levels regularly, especially if you experience symptoms of hypoglycemia such as dizziness, sweating, or confusion. Report any unusual symptoms to your healthcare provider promptly. If you experience a serious adverse reaction, seek emergency medical attention immediately or call 911. You can report side effects to the FDA's MedWatch program at 1-800-FDA-1088.
The FDA has not issued specific warnings for Glipill, but patients should be monitored for signs of hypoglycemia and renal impairment, especially in elderly patients.
The FDA has received approximately 96,589 adverse event reports associated with Glipizide-Tablets. These reports come from healthcare professionals, consumers, and manufacturers through the FDA Adverse Event Reporting System (FAERS). Note that the number of reports does not directly indicate the frequency of side effects, as adverse events are voluntarily reported and may be underrepresented.
The most frequently reported adverse events for Glipizide-Tablets include Blood Glucose Increased, Nausea, Drug Ineffective, Diarrhoea, Fatigue. By volume, the top reported reactions are: Blood Glucose Increased (5,528 reports), Nausea (3,660 reports), Drug Ineffective (3,016 reports). These figures reflect FDA adverse event reports and may not represent the true incidence rate of these side effects in all patients taking Glipizide-Tablets.
Out of 50,703 classified reports, 27,744 (54.7%) were classified as serious and 22,959 as non-serious. The FDA classifies an event as "serious" if it results in death, hospitalization, disability, or other medically significant outcomes. A higher serious-event ratio warrants closer attention but does not necessarily mean the drug is unsafe.
Adverse event reports for Glipizide-Tablets break down by patient sex as follows: Female: 24,254, Male: 24,032, Unknown: 127. This distribution reflects reporting patterns rather than actual risk differences between groups. Reporting rates can be influenced by prescribing patterns, disease demographics, and reporting behavior.
The most frequently reported age groups for Glipizide-Tablets adverse events are: age 70: 1,120 reports, age 67: 1,093 reports, age 72: 1,066 reports, age 68: 1,065 reports, age 65: 1,060 reports. Age-related reporting patterns can reflect both the demographics of the patient population and potential age-related susceptibility to certain side effects.
The primary manufacturer associated with Glipizide-Tablets adverse event reports is Ani Pharmaceuticals, Inc.. Multiple manufacturers may produce generic versions of this drug. The manufacturer listed reflects the most frequently reported brand in FDA adverse event data.
Beyond the most common reactions, other reported adverse events for Glipizide-Tablets include: Weight Decreased, Dizziness, Dyspnoea, Vomiting, Blood Glucose Decreased. Less common side effects can still be clinically significant. Patients should report any unusual symptoms to their healthcare provider.
You can report adverse events from Glipizide-Tablets to the FDA through their MedWatch program at www.fda.gov/medwatch, by calling 1-800-FDA-1088, or by completing Form FDA 3500. Healthcare professionals, consumers, and manufacturers can all submit reports. Reporting helps the FDA monitor drug safety after approval.
Glipizide-Tablets has a safety concern score of 65 out of 100 (elevated concern). This score is calculated from the ratio of serious to non-serious adverse events, the diversity of reported reactions, and the overall volume of reports relative to usage. Glipill tablets are associated with a high incidence of gastrointestinal side effects such as nausea, diarrhea, and vomiting.
Key safety signals identified in Glipizide-Tablets's adverse event data include: Hypoglycemia. Gastrointestinal issues. Renal impairment. These signals are derived from patterns in FDA reports and should be discussed with a healthcare provider for personalized assessment.
Glipill may interact with other drugs, such as beta-blockers, ACE inhibitors, and diuretics, potentially leading to hypoglycemia or other adverse effects. Patients should inform their healthcare provider of all medications they are taking. Always inform your healthcare provider about all medications, supplements, and over-the-counter drugs you are taking before starting Glipizide-Tablets.
Monitor blood glucose levels regularly, especially if you experience symptoms of hypoglycemia such as dizziness, sweating, or confusion. Report any unusual symptoms to your healthcare provider promptly.
Glipizide-Tablets has 96,589 adverse event reports on file with the FDA. Hypoglycemia is a significant concern, with 1,145 reports of this adverse event. The volume of reports for Glipizide-Tablets reflects both the drug's usage level and the vigilance of the reporting community.
The FDA has not issued specific warnings for Glipill, but patients should be monitored for signs of hypoglycemia and renal impairment, especially in elderly patients. For the most current regulatory information, check the FDA's drug labeling database or consult your pharmacist.
Explore other medications manufactured by ANI Pharmaceuticals, Inc. and compare their safety profiles:
The following drugs share commonly reported adverse reactions with GLIPIZIDE TABLETS:
Drugs related to GLIPIZIDE TABLETS based on therapeutic use, drug class, or shared indications: